217 related articles for article (PubMed ID: 33241266)
1. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
Podany AT; Leon-Cruz J; Hakim J; Supparatpinyo K; Omoz-Oarhe A; Langat D; Mwelase N; Kanyama C; Gupta A; Benson CA; Chaisson RE; Swindells S; Fletcher CV;
J Antimicrob Chemother; 2021 Feb; 76(3):718-721. PubMed ID: 33241266
[TBL] [Abstract][Full Text] [Related]
2. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
Haas DW; Podany AT; Bao Y; Swindells S; Chaisson RE; Mwelase N; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Baker P; Fletcher CV
Pharmacogenet Genomics; 2021 Jan; 31(1):17-27. PubMed ID: 32815870
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Pham MM; Podany AT; Mwelase N; Supparatpinyo K; Mohapi L; Gupta A; Samaneka W; Omoz-Oarhe A; Langat D; Benson CA; Chaisson RE; Swindells S; Fletcher CV
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0238521. PubMed ID: 35943252
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ;
Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629
[TBL] [Abstract][Full Text] [Related]
6. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Podany AT; Pham M; Sizemore E; Martinson N; Samaneka W; Mohapi L; Badal-Faesen S; Dawson R; Johnson JL; Mayanja H; Lalloo U; Whitworth WC; Pettit A; Campbell K; Phillips PPJ; Bryant K; Scott N; Vernon A; Kurbatova EV; Chaisson RE; Dorman SE; Nahid P; Swindells S; Dooley KE; Fletcher CV
Clin Infect Dis; 2022 Sep; 75(4):560-566. PubMed ID: 34918028
[TBL] [Abstract][Full Text] [Related]
9. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
McIlleron H; Denti P; Cohn S; Mashabela F; Hoffmann JD; Shembe S; Msandiwa R; Wiesner L; Velaphi S; Lala SG; Chaisson RE; Martinson N; Dooley KE;
J Antimicrob Chemother; 2017 Jul; 72(7):2028-2034. PubMed ID: 28419277
[TBL] [Abstract][Full Text] [Related]
10. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
[TBL] [Abstract][Full Text] [Related]
11. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
13. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
Enimil A; Antwi S; Yang H; Dompreh A; Alghamdi WA; Gillani FS; Orstin A; Bosomtwe D; Opoku T; Norman J; Wiesner L; Langaee T; Peloquin CA; Court MH; Greenblatt DJ; Kwara A
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332062
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE
Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955
[TBL] [Abstract][Full Text] [Related]
15. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
Phaisal W; Albitar O; Chariyavilaskul P; Jantarabenjakul W; Wacharachaisurapol N; Ghadzi SMS; Zainal H; Harun SN
J Antimicrob Chemother; 2024 Jun; 79(6):1270-1278. PubMed ID: 38661209
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
17. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
[TBL] [Abstract][Full Text] [Related]
18. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
19. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
[TBL] [Abstract][Full Text] [Related]
20. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Jarrett RT; van der Heijden Y; Shotwell MS; Chihota V; Marzinke MA; Chaisson RE; Dooley KE; Churchyard GJ
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0129722. PubMed ID: 36622148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
